General Information
Moderna Vaccine mRNA-1647-P301
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
| Protocol | mRNA-1647-P301 |
|---|---|
| Identifier | |
| UID | 050bee31-6963-4213-b510-40649af74fd0 |
| Status | Follow-up |
| Phase | 3 |
| Category | Vaccine / Adult |
| Launch Year | 2023 |
| NCT Number | - |
| Created | 2023-01-20 14:37 |
| Last Updated | 2023-10-31 17:33 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2023-06-21 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2023-04-04 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | No | |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Andujo, Darlene | DCano | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | ModernaTX, Inc. |
|---|---|
| Division | Moderna |
| Team | Moderna |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | PPD Investigator Services, LLC |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | PaleGoldenrod |
| Currency | - |
